IRWD - Ironwood Pharmaceuticals Inc.

IRWD Stock Chart

IRWD Profile

Ironwood Pharmaceuticals, Inc., headquartered in Boston, Massachusetts, operates as a healthcare company focused on advancing gastrointestinal (GI) therapies. Established in 1998 and originally known as Microbia, Inc., the company rebranded to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood specializes in the development and commercialization of innovative treatments for GI disorders, prominently featuring LINZESS (linaclotide), a guanylate cyclase type-C agonist marketed in the United States and Mexico for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC), and under the CONSTELLA name in Canada and the European Union.

In addition to LINZESS, Ironwood is actively advancing a robust pipeline of therapeutic candidates. Among these is IW-3300, another GC-C agonist designed to address visceral pain conditions such as interstitial cystitis/bladder pain syndrome and endometriosis. The company is also developing CNP-104, an immune nanoparticle targeted at treating biliary cholangitis, reflecting Ironwood's commitment to expanding its portfolio and addressing unmet medical needs.

Ironwood Pharmaceuticals maintains strategic partnerships with leading pharmaceutical entities including AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc., enhancing its capabilities in the development and commercialization of novel therapies. These collaborations underscore Ironwood's collaborative approach to innovation and its dedication to delivering breakthrough treatments to patients globally.

With a strong foundation in scientific research and a focus on patient-centric solutions, Ironwood Pharmaceuticals continues to drive advancements in GI healthcare. By leveraging its expertise in GC-C agonists and immune nanoparticle technologies, the company aims to redefine standards of care and improve the quality of life for individuals suffering from gastrointestinal and related disorders.

IRWD Revenue Chart

IRWD Earnings

Analyst Ratings